Endothelial glycocalyx in health and kidney disease: Rising star or false Dawn?

Nephrology

Volumn 22, Issue 12, 2017, Pages 940-946

  Liew, Hui ^a   Roberts, Matthew A ^a   MacGinley, Robert ^a   McMahon, Lawrence P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

albuminuria; chronic kidney disease; endothelium; glycocalyx; microcirculation

Indexed keywords

ALBUMIN; CARBOHYDRATE; HYALURONIC ACID; HYDROCORTISONE; POLYPHENOL; PROTEIN; RECOMBINANT VASCULOTROPIN; SPIRONOLACTONE; SULODEXIDE; SYNDECAN 1; BIOLOGICAL MARKER;

ATOMIC FORCE MICROSCOPY; BLOOD VESSEL INJURY; CELL SURFACE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; DISEASE MARKER; ELECTRON MICROSCOPY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL GLYCOCALYX; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULOPATHY; GLYCOCALYX; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MICROALBUMINURIA; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; VASCULAR ENDOTHELIAL CELL; ALBUMINURIA; CHEMISTRY; COMPLICATION; ENDOTHELIUM CELL; PHYSIOLOGY; VASCULAR DISEASE;

ALBUMINURIA; BIOMARKERS; ENDOTHELIAL CELLS; GLYCOCALYX; HUMANS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR DISEASES;

EID: 85033802912     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.13161     Document Type: Review

References (74)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108 (17): 2154–69.
2. Carrero JJ, Stenvinkel P. Cardiovascular disease risk factors in chronic kidney disease: Traditional, nontraditional, and uremia-related threats. In: Berbari AE, Mancia G (eds). Springer (Milan Italy): Cardiorenal Syndrome: Mechanisms, Risks and Treatment, 2010; 91–102. Chapter 7.
3. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand. J. Urol. Nephrol. 2004; 38 (5): 405–16.
4. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83 (2): 205–9.
5. Miranda CH, de Carvalho Borges M, Schmidt A, Marin-Neto JA, Pazin-Filho A. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome. Atherosclerosis 2016; 247: 184–8.
6. Nieuwdorp M, Meuwese MC, Mooij HL et al. Measuring endothelial glycocalyx dimensions in humans: A potential novel tool to monitor vascular vulnerability. J. Appl. Physiol. 2008; 104 (3): 845–52.
7. Padberg JS, Wiesinger A, di Marco GS et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234 (2): 335–43.
8. Vlahu CA, Lemkes BA, Struijk DG, Koopman MG, Krediet RT, Vink H. Damage of the endothelial glycocalyx in dialysis patients. J. Am. Soc. Nephrol. 2012; 23 (11): 1900–8.
9. Dane MJ, Khairoun M, Lee DH et al. Association of kidney function with changes in the endothelial surface layer. Clin. J. Am. Soc. Nephrol. 2014; 9 (4): 698–704.
10. Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathieson PW. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J. Am. Soc. Nephrol. 2007; 18 (11): 2885–93.
11. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch. 2000; 440 (5): 653–66.
12. Rostgaard J, Qvortrup K. Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc. Res. 1997; 53 (1): 1–13.
13. Hjalmarsson C, Johansson BR, Haraldsson B. Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc. Res. 2004; 67 (1): 9–17.
14. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy. Br. J. Anaesth. 2012; 108 (3): 384–94.
15. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch. 2007; 454 (3): 345–59.
16. Alphonsus CS, Rodseth RN. The endothelial glycocalyx: A review of the vascular barrier. Anaesthesia 2014; 69 (7): 777–84.
17. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 2007; 9: 121–67.
18. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 2008; 88 (2): 451–87.
19. Marki A, Esko JD, Pries AR, Ley K. Role of the endothelial surface layer in neutrophil recruitment. J. Leukoc. Biol. 2015; 98 (4): 503–15.
20. Oberleithner H. Vascular endothelium: A vulnerable transit zone for merciless sodium. Nephrol. Dial. Transplant. 2014; 29 (2): 240–46.
21. Chelazzi C, Villa G, Mancinelli P, De Gaudio AR, Adembri C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit. Care 2015; 19: 26.
22. Nieuwdorp M, Mooij HL, Kroon J et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55 (4): 1127–32.
23. Oberleithner H, Peters W, Kusche-Vihrog K et al. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch. 2011; 462 (4): 519–28.
24. Schott U, Solomon C, Fries D, Bentzer P. The endothelial glycocalyx and its disruption, protection and regeneration: A narrative review. Scand. J. Trauma Resusc. Emerg. Med. 2016; 24: 48.
25. Zullo JA, Fan J, Azar TT et al. Exocytosis of endothelial lysosome-related organelles hair-triggers a patchy loss of glycocalyx at the onset of sepsis. Am. J. Pathol. 2016; 186 (2): 248–58.
26. Yang Y, Yang G, Schmidt EP. In vivo measurement of the mouse pulmonary endothelial surface layer. J Vis. Exp. 2013; 72: e50322.
27. Schierke F, Wyrwoll MJ, Wisdorf M et al. Nanomechanics of the endothelial glycocalyx contribute to Na+−induced vascular inflammation. Sci. Rep. 2017; 7: 46476.
28. Mulivor AW, Lipowsky HH. Role of glycocalyx in leukocyte-endothelial cell adhesion. Am. J. Physiol. Heart Circ. Physiol. 2002; 283 (4): H1282–91.
29. Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer: Implications for platelet-endothelial cell adhesion. Circulation 2000; 101 (13): 1500–2.
30. Peters W, Druppel V, Kusche-Vihrog K, Schubert C, Oberleithner H. Nanomechanics and sodium permeability of endothelial surface layer modulated by hawthorn extract WS 1442. PLoS One 2012; 7 (1): e29972.
31. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ. Res. 2003; 92 (6): 592–4.
32. Maksimenko AV, Turashev AD. No-reflow phenomenon and endothelial glycocalyx of microcirculation. Biochem. Res. Int. 2012; 2012: 859231.
33. Potter DR, Jiang J, Damiano ER. The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circ. Res. 2009; 104 (11): 1318–25.
34. Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am. J. Physiol. 1999; 277(2 Pt 2): H508–14.
35. Broekhuizen LN, Lemkes BA, Mooij HL et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53 (12): 2646–55.
36. Nieuwdorp M, van Haeften TW, Gouverneur MC et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55 (2): 480–86.
37. Chappell D, Jacob M, Paul O et al. The glycocalyx of the human umbilical vein endothelial cell: An impressive structure ex vivo but not in culture. Circ. Res. 2009; 104 (11): 1313–7.
38. Potter DR, Damiano ER. The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is absent in vitro. Circ. Res. 2008; 102 (7): 770–76.
39. Lee DH, Dane MJ, van den Berg BM et al. Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion. PLoS One 2014; 9 (5): e96477.
40. Dane MJ, van den Berg BM, Lee DH et al. A microscopic view on the renal endothelial glycocalyx. Am. J. Physiol. Renal Physiol. 2015; 308 (9): F956–66.
41. Ward BJ, Donnelly JL. Hypoxia induced disruption of the cardiac endothelial glycocalyx: Implications for capillary permeability. Cardiovasc. Res. 1993; 27 (9): 384–9.
42. Czarnowska E, Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Basic Res. Cardiol. 1995; 90 (5): 357–64.
43. van den Berg BM, Spaan JA, Rolf TM, Vink H. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am. J. Physiol. Heart Circ. Physiol. 2006; 290 (2): H915–20.
44. Ueno M, Sakamoto H, Liao YJ et al. Blood-brain barrier disruption in the hypothalamus of young adult spontaneously hypertensive rats. Histochem. Cell Biol. 2004; 122 (2): 131–7.
45. Kumase F, Morizane Y, Mohri S, Takasu I, Ohtsuka A, Ohtsuki H. Glycocalyx degradation in retinal and choroidal capillary endothelium in rats with diabetes and hypertension. Acta Med. Okayama 2010; 64 (5): 277–83.
46. Amraoui F, Olde Engberink RH, van Gorp J, Ramdani A, Vogt L, van den Born BJ. Microvascular glycocalyx dimension estimated by automated SDF imaging is not related to cardiovascular disease. Microcirculation 2014; 21 (6): 499–505.
47. Mulders TA, Nieuwdorp M, Stroes ES, Vink H, Pinto-Sietsma SJ. Non-invasive assessment of microvascular dysfunction in families with premature coronary artery disease. Int. J. Cardiol. 2013; 168 (5): 5026–8.
48. Martens RJ, Vink H, van Oostenbrugge RJ, Staals J. Sublingual microvascular glycocalyx dimensions in lacunar stroke patients. Cerebrovasc. Dis. 2013; 35 (5): 451–4.
49. Vlahu CA, Lopes Barreto D, Struijk DG, Vink H, Krediet RT. Is the systemic microvascular endothelial glycocalyx in peritoneal dialysis patients related to peritoneal transport? Nephron Clin. Pract. 2014; 128 (1-2): 159–65.
50. Snoeijs MG, Vink H, Voesten N et al. Acute ischemic injury to the renal microvasculature in human kidney transplantation. Am. J. Physiol. Renal Physiol. 2010; 299 (5): F1134–40.
51. Kensinger C, Bian A, Fairchild M et al. Long term evolution of endothelial function during kidney transplantation. BMC Nephrol. 2016; 17 (1): 160.
52. Oflaz H, Turkmen A, Turgut F et al. Changes in endothelial function before and after renal transplantation. Transpl. Int. 2006; 19 (4): 333–7.
53. Cross JM, Donald A, Vallance PJ, Deanfield JE, Woolfson RG, MacAllister RJ. Dialysis improves endothelial function in humans. Nephrol. Dial. Transplant. 2001; 16 (9): 1823–9.
54. Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr. Hypertens. Rep. 2010; 12 (5): 364–8.
55. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The endothelial glycocalyx: A potential barrier between health and vascular disease. Curr. Opin. Lipidol. 2005; 16 (5): 507–11.
56. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J. Am. Soc. Nephrol. 2006; 17 (8): 2112–9.
57. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J. Am. Soc. Nephrol. 2006; 17 (8): 2106–11.
58. Singh A, Satchell SC. Microalbuminuria: Causes and implications. Pediatr. Nephrol. 2011; 26 (11): 1957–65.
59. Dane MJ, van den Berg BM, Avramut MC et al. Glomerular endothelial surface layer acts as a barrier against albumin filtration. Am. J. Pathol. 2013; 182 (5): 1532–40.
60. Jeansson M, Bjorck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J. Am. Soc. Nephrol. 2009; 20 (1): 114–22.
61. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: Albuminuria and increased microvascular permeability. J. Pathol. 2012; 226 (4): 562–74.
62. Salmito FT, de Oliveira Neves FM, Meneses GC, de Almeida Leitao R, Martins AM, Liborio AB. Glycocalyx injury in adults with nephrotic syndrome: Association with endothelial function. Clin. Chim. Acta 2015; 447: 55–8.
63. Peters W, Kusche-Vihrog K, Oberleithner H, Schillers H. Cystic fibrosis transmembrane conductance regulator is involved in polyphenol-induced swelling of the endothelial glycocalyx. Nanomedicine 2015; 11 (6): 1521–30.
64. Beresewicz A, Czarnowska E, Maczewski M. Ischemic preconditioning and superoxide dismutase protect against endothelial dysfunction and endothelium glycocalyx disruption in the postischemic guinea-pig hearts. Mol. Cell. Biochem. 1998; 186 (1-2): 87–97.
65. Chappell D, Jacob M, Hofmann-Kiefer K et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology 2007; 107 (5): 776–84.
66. Gao SL, Zhang Y, Zhang SY, Liang ZY, WQ Y, Liang TB. The hydrocortisone protection of glycocalyx on the intestinal capillary endothelium during severe acute pancreatitis. Shock 2015; 43 (5): 512–7.
67. Oltean S, Qiu Y, Ferguson JK et al. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J. Am. Soc. Nephrol. 2015; 26 (8): 1889–904.
68. Garsen M, Lenoir O, Rops AL et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J. Am. Soc. Nephrol. 2016; 27 (12): 3545–51.
69. Boels MG, Avramut MC, Koudijs A et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes 2016; 65 (8): 2429–39.
70. Song JW, Zullo JA, Liveris D, Dragovich M, Zhang XF, Goligorsky MS. Therapeutic restoration of endothelial glycocalyx in sepsis. J. Pharmacol. Exp. Ther. 2017; 361: 115–21.
71. Gambaro G, Kinalska I, Oksa A et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The di.N.A.S. Randomized trial. J. Am. Soc. Nephrol. 2002; 13: 1615–25.
72. Lewis EJ, Lewis JB, Greene T et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: A randomized controlled trial. Am. J. Kidney Dis. 2011; 58 (5): 729–36.
73. Meuwese MC, Mooij HL, Nieuwdorp M et al. Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J. Lipid Res. 2009; 50 (1): 148–53.
74. Nieuwdorp M, Meuwese MC, Mooij HL et al. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 2009; 202 (1): 296–303.